VA
ADAP

VR Adviser’s Adaptimmune Therapeutics ADAP Stock Holding History

VR Adviser’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-781,940
Closed -$7.83M – 23
2020
Q2 		$7.83M Buy
+781,940
New +$4.91M 1.87% 14

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser's ADAP Position: Q3 2020 in Review

VR Adviser sold out of Adaptimmune Therapeutics (ADAP) in Q3 2020, closing a stake of 781,940 shares — an estimated $7.83M sold.

VR Adviser first reported a position in ADAP in Q2 2020 and held it in 1 quarter. The position peaked at $7.83M in Q2 2020. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2020.

  • VR Adviser reported no remaining Adaptimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • VR Adviser sold 781,940 Adaptimmune Therapeutics shares in Q3 2020, an estimated $7.83M.
  • VR Adviser first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 1 quarter.
  • VR Adviser's Adaptimmune Therapeutics position peaked at $7.83M in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2020.

Based on VR Adviser's 13F filing for Q3 2020, filed 16 Nov 2020.